Quantifying Mesenchymal Stem Cells in the Mononuclear Cell Fraction of Bone Marrow Samples Obtained for Cell Therapy

Álvarez-Viejo, Marı́a; Menéndez-Menéndez, Yolanda; Blanco-Gelaz, Miguel Ángel; Ferrero-Gutiérrez, Amaia; Fernández-Rodríguez, Miguel Ángel; Gala, J García; Otero, Jesús María Garagorri

doi:10.1016/j.transproceed.2012.05.091

Cited by 99 publications

(73 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of plerixafor in the mobilization protocols overcomes the impaired HSC mobilization caused by hyperglycemia in patients with DM [61,64]. Also, studies have shown that: (1) BM-derived MSCs are better tolerated and more effective than BM-mononuclear cells for increasing limb perfusion and promoting healing of foot ulcers in patients with DM and critical limb ischemia, and (2) the success of cellular therapy is independent of the number of MSCs present in the BM aspirate used in autologous stem cell therapy [65,66]. Hyperglycemia, DM and metabolic syndrome are well known complications of HSCT particularly the allogeneic forms [67][68][69].…”

Section: Journal Of Stem Cell Biology and Transplantation Issn 2575-7725mentioning

confidence: 99%

Cure of Insulin-Dependent Diabetes Mellitus by an Autologous Hematopoietic Stem Cell Transplantation Performed to Control Multiple Myeloma in a Patient with Chronic Renal Failure on Regular Hemodialysis

Ka¹,

Bakhit²,

Alsagheir³

et al. 2017

J. Stem Cell Biol. Transplant.

View full text Add to dashboard Cite

Section: Journal Of Stem Cell Biology and Transplantation Issn 2575-7725mentioning

confidence: 99%

Cure of Insulin-Dependent Diabetes Mellitus by an Autologous Hematopoietic Stem Cell Transplantation Performed to Control Multiple Myeloma in a Patient with Chronic Renal Failure on Regular Hemodialysis

Ka¹,

Bakhit²,

Alsagheir³

et al. 2017

J. Stem Cell Biol. Transplant.

View full text Add to dashboard Cite

“…77 Defining dose in heterogeneous cell populations can also be difficult, but perhaps subpopulation composition may be less relevant (given BMMNC:MSC ratios resulted in similar clinical improvements). 94 Efficacy is most likely related to a minimum required dose, 93 while the lack of consensus may be related to inconsistent methodologies (eg, wound type, cell type, harvest, expansion, and administration). Increasing stem cell potency with adjuvants such as platelet-rich plasma or Panax notoginseng saponins are possible alternatives for decreasing the minimum required dose.…”

Section: Improving Stem Cell Yield Efficacy and Lifespan -Current Amentioning

confidence: 99%

Stem cells and chronic wound healing: state of the art

Leavitt¹,

Hu²,

Barnes³

et al. 2016

CWCMR

View full text Add to dashboard Cite

Currently available treatments for chronic wounds are inadequate. A clearly effective therapy does not exist, and treatment is often supportive. This is largely because the cellular and molecular processes underlying failure of wound repair are still poorly understood. With an increase in comorbidities, such as diabetes and vascular disease, as well as an aging population, the incidence of these intractable wounds is expected to rise. As such, chronic wounds, which are already costly, are rapidly growing as a tremendous burden to the health-care system. Stem cells have garnered much interest as a therapy for chronic wounds due to their inherent ability to differentiate into multiple lineages and promote regeneration. Herein, we discuss the types of stem cells used for chronic wound therapy, as well as the proposed means by which they do so. In particular, we highlight mesenchymal stem cells (including adipose-derived stem cells), endothelial progenitor cells, and induced pluripotent stem cells. We include the results of recent in vitro and in vivo studies in both animal models and human clinical trials. Finally, we discuss the current studies to improve stem cell therapies and the limitations of stem cell-based therapeutics. Stem cells promise improved therapies for healing chronic wounds, but further studies that are well-designed with standardized protocols are necessary for fruition.

show abstract

“…Клеточный состав КМ неоднородный по проис-хождению и морфологии; клетки КМ представле-ны на разных стадиях своего развития, среди них значительный процент составляют мононуклеар-ные клетки КМ (bone marrow mononuclear cells / BMMNCs) [169,170]. К популяции BMMNCs при-нято относить все клетки КМ, которые имеют одно ядро и не содержат гранулы в цитоплазме.…”

Section: мононуклеарные клетки костного мозгаunclassified

Therapeutic Angiogenesis by Growth Factors and Bone Marrow Mononuclear Cells Administration: Biological Foundation and Clinical Prospects

Bulgin¹,

Андреева

2015

RJTAO

View full text Add to dashboard Cite

Angiogenesis is the process of new capillary formation by migration and proliferation of differentiated endothelial cells from pre-existing microvascular network. A number of angiogenic molecules and cell populations are involved in this complex of new vessel formation cascades resulting in the determination and organization of new tridimensional vascular network. The goal of therapeutic angiogenesis is to stimulate angiogenesis to improve perfusion, to deliver survival factors to sites of tissue repair, to mobilize regenerative stem cell populations, andultimately to restore form and function to the tissue. Growth factors and bone marrow as a source of bone marrow mononuclear cells represent a very interesting research fi eld for the realization of therapeutic angiogenesis in ischemic tissues. They provide a potential key component in the healing processes of ischemic injured tissues.

show abstract

Quantifying Mesenchymal Stem Cells in the Mononuclear Cell Fraction of Bone Marrow Samples Obtained for Cell Therapy

Cited by 99 publications

References 39 publications

Cure of Insulin-Dependent Diabetes Mellitus by an Autologous Hematopoietic Stem Cell Transplantation Performed to Control Multiple Myeloma in a Patient with Chronic Renal Failure on Regular Hemodialysis

Cure of Insulin-Dependent Diabetes Mellitus by an Autologous Hematopoietic Stem Cell Transplantation Performed to Control Multiple Myeloma in a Patient with Chronic Renal Failure on Regular Hemodialysis

Stem cells and chronic wound healing: state of the art

Therapeutic Angiogenesis by Growth Factors and Bone Marrow Mononuclear Cells Administration: Biological Foundation and Clinical Prospects

Contact Info

Product

Resources

About